King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
Sci Rep. 2021 Jan 8;11(1):14. doi: 10.1038/s41598-020-79699-9.
The purpose of the study was to assess both anatomic and functional outcomes between short-pulse continuous wavelength and infrared micropulse lasers in the treatment of DME. This was a prospective interventional study from tertiary care eye hospital-King Khaled Eye Specialist Hospital (Riyadh, Saudi Arabia). Patients with center-involving diabetic macular edema were treated with subthreshold laser therapy. Patients in the micropulse group were treated with the 810-nm diode micropulse scanning laser TxCell (IRIDEX Corporation, Mountain View, CA, USA) (subthreshold micropulse-STMP group). Laser was applied according to recommendations for MicroPulse (125 microns spot size, 300 ms pulse duration and power adjustment following barely visible testing burn) in a confluent mode (low intensity/high density) to the entire area of the macular edema. Patients in the short-pulse group were treated with grid pattern laser with 20 ms pulse PASCAL laser 532 nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn (EndPoint 30% and EndPoint 50% groups, respectively). Main outcome measures included best-corrected visual acuity (BCVA in logMAR) and foveal thickness at baseline and the last follow-up visit at 6 months. There were 44 eyes in the micropulse group, 54 eyes in the EndPoint 50% group and 18 eyes in the EndPoint 30% group. BCVA for the whole cohort (logMAR) was 0.451 (Snellen equivalent 20/56) at baseline, 0.495 (Snellen equivalent 20/62) (p = 0.053) at 3 months, and 0.494 (Snellen equivalent 20/62) at the last follow-up (p = 0.052). Foveal thickness for the whole cohort was 378.2 ± 51.7 microns at baseline, 347.2 ± 61.3 microns (p = 0.002) at 3 months, and 346.0 ± 24.6 microns at the final follow-up (p = 0.027). As such the short-pulse system yields more temporary reduction in edema. Comparison of BCVA between baseline and 6 months for EndPoint 30%, EndPoint 50% and STMP groups was p = 0.88, p = 0.76 and p = 0.003, respectively. Comparison of foveal thickness between baseline and 6 months for EndPoint 30%, EndPoint 50% and STMP groups was p = 0.38, p = 0.22 and p = 0.14, respectively. We conclude that the infrared micropulse system seems to improve functional outcomes. When applied according to previously published reports, short-pulse system may yield more temporary reduction in edema while infrared micropulse system may yield slightly better functional outcomes.
研究目的在于评估短脉冲连续波长和红外微脉冲激光治疗 DME 的解剖和功能结果。这是来自三级眼科医院——沙特阿拉伯利雅得 King Khaled 眼科专科医院的一项前瞻性干预性研究。中心性糖尿病黄斑水肿患者接受阈下激光治疗。微脉冲组患者接受 810nm 二极管微脉冲扫描激光 TxCell(IRIDEX 公司,加利福尼亚州山景城)(亚阈微脉冲-STMP 组)治疗。根据微脉冲的建议应用激光(125 微米光斑大小,300 毫秒脉冲持续时间和根据几乎看不见的测试烧伤进行的功率调整)以连续模式(低强度/高密度)在黄斑水肿的整个区域进行治疗。短脉冲组患者接受 532nm 脉冲 PASCAL 激光 20ms 脉冲格栅模式治疗(TopCon Medical Laser Systems,东京,日本),采用终点算法,为测试烧伤的 30%或 50%(分别为终点 30%和终点 50%组)。主要观察指标包括最佳矫正视力(logMAR 中的 BCVA)和基线及 6 个月最后一次随访时的中心凹厚度。微脉冲组有 44 只眼,终点 50%组有 54 只眼,终点 30%组有 18 只眼。整个队列的 BCVA(logMAR)基线时为 0.451(Snellen 等效值 20/56),3 个月时为 0.495(Snellen 等效值 20/62)(p=0.053),最后一次随访时为 0.494(Snellen 等效值 20/62)(p=0.052)。整个队列的中心凹厚度基线时为 378.2±51.7 微米,3 个月时为 347.2±61.3 微米(p=0.002),最后一次随访时为 346.0±24.6 微米(p=0.027)。因此,短脉冲系统可暂时更多地减轻水肿。终点 30%、终点 50%和 STMP 组之间的 BCVA 比较,基线和 6 个月时分别为 p=0.88、p=0.76 和 p=0.003。终点 30%、终点 50%和 STMP 组之间的中心凹厚度比较,基线和 6 个月时分别为 p=0.38、p=0.22 和 p=0.14。我们得出结论,红外微脉冲系统似乎可以改善功能结果。按照先前发表的报告应用时,短脉冲系统可能会暂时更多地减轻水肿,而红外微脉冲系统可能会产生稍微更好的功能结果。